Patrys Limited Product Industry Segmentation and Forecast 2015

1
Patrys Limited - Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About Patrys Limited - Product Pipeline Review -
2015 Research Beam added report on Patrys
Limited Product Pipeline Review - 2015. Patrys
Limited Product Pipeline Review 2015
Summary Global Markets Directs, Patrys Limited
Product Pipeline Review - 2015, provides an
overview of the Patrys Limited s Patrys Limited
research and development focus. This report
provides comprehensive information on the current
therapeutic developmental pipeline of Patrys
Limited s, complete with comparative analysis at
various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of
administration (RoA) and molecule type. It also
reviews latest updates, and featured news and
press releases, along with special features on
late-stage and discontinued projects. Get Full
Details On http//www.researchbeam.com/patrys-li
mited-product-pipeline-review-2015-market

3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.
4
.
Report Overview
Scope The report provides brief overview of
Patrys Limited including business description,
key information and facts, and its locations and
subsidiaries The report reviews current pipeline
of Patrys Limited s human therapeutic division
and enlists all their major and minor
projects The report features product description
and descriptive mechanism of action for key
pipeline products along with the products
developmental history and major milestones
Special feature on out-licensed and partnered
product portfolio The report summarizes all the
dormant and discontinued pipeline projects Latest
company statement Latest news and deals relating
to the Patrys Limited s pipeline products  
5
Report Overview

• Reasons to buy
•  Evaluate Patrys Limited s strategic position
  with total access to detailed information on its
  product pipeline
• Assess the growth potential of Patrys Limited in
  its therapy areas of focus
• Identify new drug targets and therapeutic classes
  in the Patrys Limited s RD portfolio and develop
  key strategic initiatives to reinforce pipeline
  in those areas
• Exploit in-licensing opportunities by identifying
  windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding
  the focus areas of Patrys Limited and exploit
  collaboration and partnership opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of Patrys
  Limited
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Patrys Limited and identify potential
  opportunities in those areas

6
Table Of Contents
Table of Contents 2List of Tables 6List of
Figures 6Patrys Limited Snapshot 7Patrys
Limited Overview 7Key Information 7Key Facts
7Patrys Limited - Research and Development
Overview 8Key Therapeutic Areas 8Patrys Limited
- Pipeline Review 11Pipeline Products by Stage
of Development 11Pipeline Products - Monotherapy
12Pipeline Products - Combination Treatment
Modalities 13Pipeline Products - Partnered
Products 14
7
Table Of Contents
Partnered Products/Combination Treatment
Modalities 15Pipeline Products - Out-Licensed
Products 16Out-Licensed Products/Combination
Treatment Modalities 17Patrys Limited - Pipeline
Products Glance 18Patrys Limited - Late Stage
Pipeline Products 18 Partnered Products/Combinatio
n Treatment Modalities 15Pipeline Products -
Out-Licensed Products 16Out-Licensed
Products/Combination Treatment Modalities
17Patrys Limited - Pipeline Products Glance
18Patrys Limited - Late Stage Pipeline Products
18
8
Table Of Contents
Pre-Registration Products/Combination Treatment
Modalities 18Filing rejected/Withdrawn
Products/Combination Treatment Modalities
19Phase III Products/Combination Treatment
Modalities 20Patrys Limited - Clinical Stage
Pipeline Products 21Phase II Products/Combination
Treatment Modalities 21Phase I
Products/Combination Treatment Modalities
22Patrys Limited - Early Stage Pipeline Products
23Preclinical Products/Combination Treatment
Modalities 23Discovery Products/Combination
Treatment Modalities 24 Enquiry about this
report _at_ http//www.researchbeam.com/patrys-limite
d-product-pipeline-review-2015-market/enquire-abou
t-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/patrys-limited-product
-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com